Seelos Therapeutics Announces Appointment of Judith Dunn to the Board of Directors
2020年5月15日 - 11:30PM
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage
biopharmaceutical company focused on the development of therapies
for central nervous system disorders and rare diseases, announced
today the appointment of Judith Dunn, Ph.D. to its Board of
Directors.
Dr. Dunn has had an extensive career in the pharmaceutical and
biotechnology industries having served in various roles at F.
Hoffman-La Roche AG from March 2010 through January 2018, including
Vice President, Global Head of Clinical Development and Principal
Medical Group Leader, Neuroscience. She also served as the
Executive Medical Director, CNS Clinical Development (Ph I-III) at
Sepracor, Inc. from 2005 to 2010 and in a number of roles at Pfizer
Inc. from 1997 to 2005, including Director, Worldwide Medical
Affairs, Antipsychotics, Senior Associate Director, Global
Candidate Leader, CNS Development and Associate Director, CNS
Development.
“It’s our privilege and honor to have Judy on our board as she
brings a unique combination of clinical and regulatory experience
from Roche and Pfizer in both Psychiatry and Neurology,” said Raj
Mehra, Ph.D., Chairman and CEO of Seelos. “She will be an
invaluable resource to Seelos.”
Beyond her industry experience, she has served as an
entrepreneur in residence at Atlas Venture since June 2018, as the
independent board member of Evolution Research Group since August
2018, as a member of the NYC Mayor’s Advisory Council on Life
Sciences since December 2016 and as a member of the Digital Health
Breakthrough Network Advisory Board since 2017. Prior to that, she
served as the chairman of the board of NYBIO from June 2016 to June
2018, as a board member of the Swiss American Foundation from
January 2014 to January 2018, as a board member of the Partnership
for NY Fund from 2014 to 2016 and as a board member of BioHealth
Innovation Maryland from 2014 to 2015.
Dr. Dunn received a Postdoctoral Fellowship in New Drug
Development from Pfizer, a Training Fellowship in Neuropharmacology
from the Center for Brain Research, a Doctor of Philosophy,
Developmental Neurobiology from Wesleyan University and a Bachelor
of Science, Neurobiology from the University of Rochester.
Contact Information: Anthony Marciano Head of Corporate
Communications Seelos Therapeutics, Inc. (Nasdaq: SEEL) 300 Park
Ave., 12th Fl New York, NY 10022 (646) 293-2136
anthony.marciano@seelostx.com
www.seelostherapeutics.com
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos
Seelos Therapeutics (NASDAQ:SEEL)
過去 株価チャート
から 8 2024 まで 9 2024
Seelos Therapeutics (NASDAQ:SEEL)
過去 株価チャート
から 9 2023 まで 9 2024